CloudFirst Divestiture -- The sale of the CloudFirst business closed on September 11, 2025, for $40 million, removing an ...
The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly ...
Against the backdrop of growing demand for global ubiquitous connectivity in the 6G era, low-Earth-orbit (LEO) satellite mega-constellations have ...
Fox will integrate Kalshi forecasts across its news and streaming platforms as prediction markets gain mainstream media reach.
Fox Corp said on Tuesday it will integrate Kalshi's prediction market data across its news and streaming platforms, ...
In the announcement, FDA Commissioner Mackary said, “Bayesian methodologies help address two of the biggest problems of drug development: high costs and long timelines. Providing clarity around modern ...
DRG5-BD11 is a human monoclonal antibody designed to target peptidoglycan and HSP16.3, two conserved bacterial antigens Data highlight potential new approach for treating antimicrobial resistance ...
The NYU Langone-Sage NDHCC will expand upon the work Sage Bionetworks has been doing for more than a decade, building infrastructure that makes collaborative biomedical research possible at scale.” — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results